# Study Guide: KEYTRUDA (pembrolizumab) Clinical and Prescribing Overview This study guide provides a comprehensive synthesis of the prescribing information and clinical trial data for KEYTRUDA (pembrolizumab). It is designed to facilitate a deep understanding of its mechanism of action, therapeutic indications, administration protocols, and safety profile. --- ## 1. Core Therapeutic Concepts and Mechanism KEYTRUDA is a programmed death receptor-1 (PD-1)-blocking antibody. It is a humanized monoclonal antibody (IgG4 kappa immunoglobulin) with an approximate molecular weight of 149 kDa. ### Mechanism of Action * **Target:** The PD-1 receptor on T cells. * **Function:** PD-1 ligands (PD-L1 and PD-L2) normally bind to the PD-1 receptor to inhibit T cell proliferation and cytokine production. Some tumors upregulate these ligands to evade immune surveillance. * **Action:** Pembrolizumab blocks the interaction between the PD-1 receptor and its ligands. This releases the PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. ### Patient Selection and Testing Selection for certain indications, specifically Non-Small Cell Lung Cancer (NSCLC), requires FDA-approved companion diagnostics: * **TPS (Tumor Proportion Score):** A measure of PD-L1 expression. * **MSI-H/dMMR:** Microsatellite Instability-High or Mismatch Repair Deficient status is required for specific solid tumor indications. --- ## 2. Clinical Indications KEYTRUDA is indicated for several types of advanced or metastatic cancers, often depending on prior treatment history or specific biomarkers. | Cancer Type | Specific Indication Criteria | | :--- | :--- | | **Melanoma** | Unresectable or metastatic melanoma. | | **NSCLC (First-line)** | Single agent for metastatic NSCLC with TPS ≥50% and no EGFR/ALK aberrations. | | **NSCLC (Combination)** | First-line treatment for metastatic nonsquamous NSCLC in combination with pemetrexed and carboplatin. | | **NSCLC (Previously Treated)** | Single agent for metastatic NSCLC with TPS ≥1% and progression on/after platinum-based chemotherapy. | | **HNSCC** | Recurrent or metastatic Head and Neck Squamous Cell Cancer with progression on/after platinum chemotherapy. | | **cHL** | Adult/pediatric patients with refractory Classical Hodgkin Lymphoma or relapse after 3+ lines of therapy. | | **Urothelial Carcinoma** | Locally advanced or metastatic patients ineligible for cisplatin or who progressed during/after platinum chemotherapy. | | **MSI-H Cancer** | Adult/pediatric patients with unresectable/metastatic MSI-H or dMMR solid tumors that progressed after prior treatment with no alternative options. | --- ## 3. Dosage and Administration ### Recommended Dosing * **Adults:** 200 mg administered every 3 weeks. * **Pediatrics:** 2 mg/kg (up to a maximum of 200 mg) every 3 weeks. * **Method:** Intravenous (IV) infusion over 30 minutes. * **Duration:** Typically until disease progression or unacceptable toxicity. For several indications, treatment can continue for up to 24 months in patients without disease progression. ### Preparation and Reconstitution 1. **Reconstitution:** For the 50 mg lyophilized powder, add 2.3 mL of Sterile Water for Injection (resulting in 25 mg/mL). Swirl slowly; do not shake. 2. **Dilution:** Withdraw the required volume and transfer it to an IV bag containing 0.9% Sodium Chloride or 5% Dextrose. The final concentration must be between 1 mg/mL and 10 mg/mL. 3. **Storage:** Store the reconstituted or diluted solution for no more than 6 hours at room temperature or 24 hours under refrigeration (2°C to 8°C). 4. **Administration:** Use an IV line with a sterile, non-pyrogenic, low-protein binding 0.2 micron to 5 micron in-line or add-on filter. --- ## 4. Safety Profile: Warnings and Precautions KEYTRUDA can cause the immune system to attack normal organs. These "immune-mediated" reactions can be severe or fatal. ### Major Immune-Mediated Adverse Reactions * **Pneumonitis:** Occurred in 3.4% of patients. Monitor for cough and shortness of breath. * **Colitis:** Monitor for diarrhea or abdominal pain. Colitis resolved in 85% of cases following corticosteroid treatment. * **Hepatitis:** Monitor for changes in liver function. Corticosteroids should be administered based on the severity of liver enzyme elevations. * **Endocrinopathies:** * **Hypophysitis:** Monitor for headache and extreme weakness. * **Thyroid Disorders:** Includes hyperthyroidism (3.4%) and hypothyroidism (8.5%). * **Type 1 Diabetes Mellitus:** Monitor for hyperglycemia. * **Nephritis:** Monitor for changes in renal function. Severe cases require permanent discontinuation. ### General Adverse Reactions The most common reactions (≥20% of patients) include: * Fatigue * Pruritus (itching) * Diarrhea * Decreased appetite * Rash * Pyrexia (fever) * Cough/Dyspnea * Musculoskeletal pain * Constipation/Nausea --- ## 5. Short-Answer Practice Questions 1. **What is the standard adult dose of KEYTRUDA and how frequently is it administered?** 2. **Which specific genomic aberrations must be absent for a patient with metastatic NSCLC to receive first-line KEYTRUDA as a single agent?** 3. **How long must females of reproductive potential use effective contraception after their final dose of KEYTRUDA?** 4. **In the event of Grade 3 or 4 infusion-related reactions, what is the required clinical action?** 5. **What are the storage temperature requirements for KEYTRUDA vials?** 6. **What is the median terminal half-life of pembrolizumab?** 7. **If a patient develops Grade 2 pneumonitis, should KEYTRUDA be withheld or permanently discontinued?** 8. **What are the three components used in the combination therapy for metastatic nonsquamous NSCLC?** --- ## 6. Essay Prompts for Deeper Exploration 1. **The Role of PD-1 Blockade in Oncology:** Explain the biological mechanism by which KEYTRUDA enhances the body's anti-tumor immune response. Contrast this with traditional chemotherapy based on the clinical trial results for NSCLC (KEYNOTE-024). 2. **Managing Immune-Mediated Toxicity:** Discuss the clinical management of immune-mediated adverse reactions. Compare the protocols for withholding versus permanently discontinuing the drug based on the severity of organ-specific toxicities. 3. **Accelerated Approval and Confirmatory Trials:** Several indications for KEYTRUDA (e.g., HNSCC, cHL, and certain Urothelial Carcinoma cohorts) were granted "accelerated approval." Discuss the criteria for this type of approval and what is required of the manufacturer to maintain it. 4. **Pharmacokinetics and Special Populations:** Analyze the pharmacokinetic profile of pembrolizumab. Discuss how factors like age, sex, and renal impairment affect clearance, and evaluate the safety findings regarding pediatric and geriatric use. --- ## 7. Glossary of Important Terms * **Allogeneic HSCT:** A stem cell transplant using donor cells; complications like GVHD may increase if performed after KEYTRUDA treatment. * **dMMR (Mismatch Repair Deficient):** A biomarker indicating a lack of proteins that repair DNA; used to identify patients for MSI-H indications. * **Embryofetal Toxicity:** The potential for a drug to cause harm to a developing fetus. * **GVHD (Graft-Versus-Host Disease):** A condition where donor immune cells attack the recipient's body, a potential complication of HSCT. * **Hypophysitis:** Inflammation of the pituitary gland; an immune-mediated side effect of KEYTRUDA. * **Immunogenicity:** The ability of a substance (like pembrolizumab) to provoke an immune response (e.g., the development of anti-product antibodies). * **MSI-H (Microsatellite Instability-High):** A genetic marker indicating a high rate of mutations in a tumor, used as a criterion for KEYTRUDA eligibility. * **Pneumonitis:** Inflammation of lung tissue, a significant potential respiratory side effect. * **TPS (Tumor Proportion Score):** The percentage of viable tumor cells showing partial or complete membrane staining for PD-L1. * **VOD (Veno-occlusive Disease):** A condition in which small blood vessels in the liver become blocked; reported as a complication in patients who had HSCT after KEYTRUDA.